Stevanato Group (STVN)
NYSE:STVN
Want to see STVN full AI Analyst Report?
Top Page
Stevanato Group
(NYSE:STVN)
Select Model
Select Model
Rating:63Neutral
Price Target:
$19.00
▲(22.34% Upside)
Action:ReiteratedDate:03/07/26
The score is anchored by solid financial stability but tempered by weaker cash flow consistency. A positive earnings-call outlook and guidance support the outlook, while bearish technicals and a relatively high P/E weigh on near-term attractiveness.
Positive Factors
High-value product mix & GLP-1 tailwind
A structural shift toward high-value products, with GLP‑1 exposure growing rapidly, improves revenue durability and pricing power. Higher-margin biologics and Nexa syringes raise average selling prices and create multi-year supply relationships, supporting sustained margin and revenue growth.
Negative Factors
Volatile cash conversion history
Despite recent improvement, multi-year volatility in free cash flow and weak cash conversion (FCF ~7.8% of net income in 2025) indicate execution and timing risks. Inconsistent cash conversion makes it harder to sustainably fund capex and service debt without pressuring liquidity during slower periods.
Read all positive and negative factors
Positive Factors
Negative Factors
High-value product mix & GLP-1 tailwind
A structural shift toward high-value products, with GLP‑1 exposure growing rapidly, improves revenue durability and pricing power. Higher-margin biologics and Nexa syringes raise average selling prices and create multi-year supply relationships, supporting sustained margin and revenue growth.
Read all positive factors
Stevanato Group (STVN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.86B
Dividend Yield0.29%
Average Volume (3M)571.78K
Price to Earnings (P/E)24.8
Beta (1Y)0.76
Revenue Growth12.70%
EPS Growth24.60%
CountryUS
Employees5,521
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)0.51
Shares Outstanding49,709,717
10 Day Avg. Volume634,716
30 Day Avg. Volume571,777
Financial Highlights & Ratios
PEG Ratio2.49
Price to Book (P/B)3.15
Price to Sales (P/S)4.10
P/FCF Ratio218.04
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue3.87
Enterprise Value/Gross Profit13.36
Enterprise Value/Ebitda16.21
Forecast
1Y Price Target
$24.50Price Target Upside57.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)0.6
Revenue Forecast (FY)$1.28B
Stevanato Group Business Overview & Revenue Model
Company Description
Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for pharma and healthcare. Its principal products include containment solutions, drug delivery systems, medical de...
How the Company Makes Money
Stevanato Group primarily makes money by selling products and services used to package, contain, and deliver injectable drugs and to support customers’ manufacturing and device-development needs. Key revenue streams include: (1) High-value drug co...
Stevanato Group Earnings Call Summary
Earnings Call Date:Mar 04, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 07, 2026
Earnings Call Sentiment Positive
The call emphasized strong execution in high-value biopharmaceutical products, with meaningful revenue and margin expansion driven by BDS, high-value solutions and GLP-1 demand; operational investments (Latina, Fishers) and positive free cash flow support the growth strategy. Key challenges include a materially weaker Engineering segment (notably lower Q4 revenue and slower order conversion), FX/tariff headwinds, heavy near-term CapEx and some capacity ramp timing risk. On balance, the positive drivers (robust top-line growth, high-value mix, margin expansion, positive FCF, and constructive 2026 guidance) significantly outweigh the identified negatives.Positive Updates
Full-Year Revenue Growth
Total company revenue for fiscal 2025 increased 9% at constant currency and 7% on a reported basis versus 2024, delivering the company guidance-backed growth and positive momentum heading into 2026.
Negative Updates
Engineering Segment Underperformance
Engineering revenue declined 23% in Q4 to EUR 39.4 million and the segment gross profit margin fell to 15.8% (operating profit margin 9.1%). Management expects Engineering revenue to decline mid-single digit to low double digits in 2026 due to lower prior order intake and slower-than-expected conversion of pipeline opportunities.
Read all updates
Q4-2025 Updates
Positive
Negative
Full-Year Revenue Growth
Total company revenue for fiscal 2025 increased 9% at constant currency and 7% on a reported basis versus 2024, delivering the company guidance-backed growth and positive momentum heading into 2026.
Read all positive updates
Company Guidance
For 2026 the company guided revenue of EUR 1.260–1.290 billion (EUR 1.278–1.308 billion at constant currency), implying ~7.5% reported growth (~8.3% cc), with Q1 expected to show mid‑single‑digit reported growth at the midpoint; adjusted EBITDA of EUR 331.8–346.9 million and adjusted diluted EPS of EUR 0.59–0.63; consolidated margin expansion of ~0–30 bps (operating margin ~+50 bps at the midpoint and adjusted EBITDA margin ~+150 bps); BDS is expected to grow high single to low double digits (double digits cc) while Engineering is expected to decline mid‑single to low double digits; high‑value solutions are forecast to represent ~47–48% of total revenue; the company assumed an FX headwind of ~EUR 18 million for 2026 (≈EUR 10 million in Q1), a tax rate of ~26.8%, CapEx of EUR 270–290 million (net of customer contributions EUR 240–260 million), and free cash flow roughly breakeven to +EUR 20 million.Stevanato Group Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
78
Positive
Cash Flow
54
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.14B | 1.10B | 1.09B | 983.68M | 843.92M |
| Gross Profit | 330.33M | 302.32M | 339.89M | 319.80M | 265.40M |
| EBITDA | 268.18M | 247.80M | 272.35M | 256.40M | 226.93M |
| Net Income | 134.28M | 117.78M | 145.63M | 142.85M | 134.32M |
Balance Sheet | |||||
| Total Assets | 2.54B | 2.33B | 2.07B | 1.66B | 1.42B |
| Cash, Cash Equivalents and Short-Term Investments | 132.74M | 98.27M | 70.35M | 256.65M | 438.21M |
| Total Debt | 470.70M | 428.97M | 396.59M | 218.37M | 244.29M |
| Total Liabilities | 1.06B | 924.43M | 938.93M | 663.79M | 577.18M |
| Stockholders Equity | 1.49B | 1.40B | 1.13B | 996.13M | 842.07M |
Cash Flow | |||||
| Free Cash Flow | 21.44M | -157.79M | -336.72M | -139.81M | 20.16M |
| Operating Cash Flow | 274.79M | 155.78M | 105.21M | 103.31M | 133.34M |
| Investing Cash Flow | -262.15M | -310.21M | -421.22M | -242.95M | -96.43M |
| Financing Cash Flow | 21.19M | 183.22M | 158.03M | -44.54M | 254.85M |
Stevanato Group Technical Analysis
Neutral
15.53
Price Trends
14.95
Positive
17.64
Negative
21.11
Negative
Market Momentum
-0.09
Negative
62.16
Neutral
87.44
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STVN, the sentiment is Neutral. The current price of 15.53 is above the 20-day moving average (MA) of 14.10, above the 50-day MA of 14.95, and below the 200-day MA of 21.11, indicating a neutral trend. The MACD of -0.09 indicates Negative momentum. The RSI at 62.16 is Neutral, neither overbought nor oversold. The STOCH value of 87.44 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for STVN.
Stevanato Group Risk Analysis
Stevanato Group disclosed 64 risk factors in its most recent earnings report. Stevanato Group reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Stevanato Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $2.54B | 29.55 | 15.58% | 0.95% | 13.53% | 30.00% | |
65 Neutral | $3.70B | 25.02 | 8.52% | ― | 11.34% | 12.26% | |
64 Neutral | $6.67B | 174.26 | 2.37% | ― | 16.36% | ― | |
63 Neutral | $4.86B | 24.79 | 9.72% | 0.29% | 12.70% | 24.60% | |
57 Neutral | $5.31B | -1.89 | -23.70% | 1.11% | -2.75% | -1515.83% | |
55 Neutral | $7.70B | 27.77 | 14.33% | 1.50% | 8.95% | 6.13% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
STVN
Stevanato Group
17.79
-3.40
-16.05%
ATR
AptarGroup
120.60
-28.77
-19.26%
LMAT
Lemaitre Vascular
111.53
30.18
37.11%
MMSI
Merit Medical Systems
62.01
-30.86
-33.23%
RGEN
Repligen
118.21
-12.19
-9.35%
TFX
Teleflex
119.89
0.70
0.58%
Stevanato Group Corporate Events
Stevanato Group Posts 2025 Growth on High-Value Syringes and GLP‑1 Demand
Mar 12, 2026
On March 4, 2026, Stevanato Group management reviewed fourth-quarter and full-year 2025 results, reporting 2025 revenue growth of 9% at constant currency and 7% on a reported basis versus 2024, driven by double-digit expansion in its Biopharmaceut...
Stevanato Group Posts Record High‑Value Revenue and Strong 2025 Results, Sets Upbeat 2026 Outlook
Mar 4, 2026
On March 4, 2026, Stevanato Group reported that fourth‑quarter 2025 revenue rose 5% year‑on‑year to €346.5 million, with high‑value solutions reaching a record 49% of sales and lifting gross and adjusted EBITDA margin...
Stevanato Group Files Form 6-K With Q4 and FY 2025 Results Presentation
Mar 4, 2026
On March 4, 2026, Stevanato Group filed a Form 6-K with the U.S. Securities and Exchange Commission, furnishing the investor presentation used for its Q4 and full-year 2025 financial results conference call. The filing, signed by CEO Franco Stevan...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.